Search results
Results from the WOW.Com Content Network
This page was last edited on 4 May 2019, at 22:48 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply ...
EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery. pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency (DERA, now QinetiQ).
The New York City Economic Development Corporation's Early Stage Life Sciences Funding Initiative and venture capital partners, including Celgene, General Electric Ventures, and Eli Lilly, committed a minimum of US$100 million to help launch 15 to 20 ventures in life sciences and biotechnology in 2014, [6] and in January 2018, the City of New ...
Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. [1] Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.
In December 2011, the company agreed to purchase 17 brands from GlaxoSmithKline including BC Powder, Beano, Ecotrin, Fiber Choice, Goody's Powder, Sominex and Tagamet for $660 million. [ 5 ] In 2013, Prestige Brands Holdings, Inc. acquired Care Pharmaceuticals of Bondi Junction, New South Wales, Australia, a privately held marketer and ...
The company developed P2Y 12 inhibitor Elinogrel, transferring rights to Novartis in 2009. [6] The rights were returned in 2012 to Portola, which decided not to continue development. Portola Pharmaceuticals has collaboration agreements with SRX Cardio, Dermavant, Millennium Pharmaceuticals, Daiichi Sankyo, Bayer, Janssen, BMS, and Pfizer. [7]
From 2019 to 2021 the company's earnings per share (EPS) increased by 4.5% every year. In 2021, the company's revenue was down by 13 percent. [11] In 2024, the company declared Chapter 11 bankruptcy protection, and announced that it had secured a "stalking horse" bid for all of its assets. As a result of the bankruptcy filing, the company's ...
The company traces its roots back to 1948 and pharmacist Gavin S. Herbert, who in 1950 established Allergan Pharmaceuticals, Inc. Allergan focused on the discovery and development of novel formulations for specialty markets, as well as intimate collaboration with physicians and the scientific community. 1953 saw Allergan producing eye drops and formulating new products such as the first ...